UK Faces Summer Flight Disruptions As Jet Fuel Risks Mount Via City AM , Ministers are expected to warn Britons that flight cancellations could disrupt summer holiday plans. Allianz Trade research says the UK is especially exposed to jet fuel shortages because of import dependence. Airlines are weighing cancellations, surcharges, and ticket price adjustments as fuel supply risks rise. Ministers ar...
UK Faces Summer Flight Disruptions As Jet Fuel Risks Mount Via City AM , Ministers are expected to warn Britons that flight cancellations could disrupt summer holiday plans. Allianz Trade research says the UK is especially exposed to jet fuel shortages because of import dependence. Airlines are weighing cancellations, surcharges, and ticket price adjustments as fuel supply risks rise. Ministers are set to warn the British public that flight cancellations will hit summer holiday plans as new research suggested that the UK is more exposed to jet fuel shortages than other European countries. Heidi Alexander, the transport secretary, is set to tell Brits that there could be flight cancellations this year as she will talk up staycations, according to The Times. Her warnings will follow a prompt by Sir Keir Starmer that people would have to consider changing “where they go on holiday”. Trade experts have warned that the supply of kerosene was set to be hit by disruptions across the Strait of Hormuz. Michael O’Leary, the boss of Ryanair, Europe’s biggest airline, said rivals were “desperately” searching for flights to cancel. Some airlines have reportedly said that the UK could escape some of the worst effects of jet fuel shortages due to obtaining supplies from other countries. UK is ‘particularly vulnerable’ to jet fuel shortages But research by Allianz Trade found the UK had Europe’s “most structurally exposed markets to jet-fuel shortages”. It said its heavy reliance on imports, albeit from countries outside of the Middle East, would leave the UK “particularly vulnerable” to supply shocks. “The UK, Germany, France, and Italy show the largest shortfalls, underscoring their reliance on external supply to meet aviation demand,” trade experts said. “European aviation activity is indirectly exposed not only to global oil price dynamics but also to geopolitical and logistical risks along key supply routes, reinforcing the region’s dependence on external refining hubs for a f...
If you had invested $20,000 in Vertex Pharmaceuticals (NASDAQ: VRTX) in its IPO in 1991 and held onto its shares, you'd have over $1 million today, considering the company's strong 14% compound annual growth rate since then, much better than the S&P 500 's 11% over the same period. Maintaining this pace over more than three decades is commendable. However, can Vertex Pharmaceuticals still perform ...
If you had invested $20,000 in Vertex Pharmaceuticals (NASDAQ: VRTX) in its IPO in 1991 and held onto its shares, you'd have over $1 million today, considering the company's strong 14% compound annual growth rate since then, much better than the S&P 500 's 11% over the same period. Maintaining this pace over more than three decades is commendable. However, can Vertex Pharmaceuticals still perform well from here on out? Image source: The Motley Fool. Vertex Pharmaceuticals has made quite a name for itself, given the company's dominance in its core market. It develops medicines for a rare disease called cystic fibrosis (CF), characterized by the accumulation of thick, sticky mucus in the lungs, which leads to a range of problems, including respiratory issues. Vertex Pharmaceuticals is the only notable player in this niche. Its portfolio of CF medicines has improved over time, enabling it to treat about 95% of CF patients in the U.S. Continue reading
Fresenius SE & Co. KGaA press release ( FSNUF ): Non-GAAP EPS of €0.82. Revenue of €5.74B (+2.0% Y/Y). Group EBIT1 at €678 million with 6% growth in constant currency. Operating cashflow of €389 million, a fourfold rise year-on-year. Net debt/EBITDA ratio improved further to 2.6x1,4 at the lower end of the self-imposed target corridor of 2.5 to 3.0x driven by strong cash flow. 2026 guidance reconf...
Fresenius SE & Co. KGaA press release ( FSNUF ): Non-GAAP EPS of €0.82. Revenue of €5.74B (+2.0% Y/Y). Group EBIT1 at €678 million with 6% growth in constant currency. Operating cashflow of €389 million, a fourfold rise year-on-year. Net debt/EBITDA ratio improved further to 2.6x1,4 at the lower end of the self-imposed target corridor of 2.5 to 3.0x driven by strong cash flow. 2026 guidance reconfirmed : Fresenius Group5: organic revenue growth2 in the range of 4% to 7%; constant currency Core EPS3 growth expected in the range of 5% to 10%; EBIT margin8 of ~11.5%. Fresenius Kabi6: organic revenue growth2 in the mid- to high-single-digit percentage range; EBIT margin of 16.5% to 17.0%. Fresenius Helios7: organic revenue growth in the mid-single-digit percentage range; EBIT margin of 10.0% to 10.5%. More on Fresenius SE & Co Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript Fresenius SE & Co. KGaA 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Fresenius SE & Co Historical earnings data for Fresenius SE & Co Dividend scorecard for Fresenius SE & Co
The chief executives at some of the largest Italian banks are girding up for more acquisitions, potentially extending a wave of transactions across the country’s finance industry. The domestic banking market is fragmented and destined for consolidation, UniCredit SpA CEO Andrea Orcel said on an analyst call Tuesday. He’s “attentive” for opportunities, he added. Banco BPM SpA CEO Giuseppe Castagna ...
The chief executives at some of the largest Italian banks are girding up for more acquisitions, potentially extending a wave of transactions across the country’s finance industry. The domestic banking market is fragmented and destined for consolidation, UniCredit SpA CEO Andrea Orcel said on an analyst call Tuesday. He’s “attentive” for opportunities, he added. Banco BPM SpA CEO Giuseppe Castagna echoed the comments on a separate analyst call , indicating he expects future transactions in the sector. “We are looking at everything — big, small opportunities,” he said. The comments highlight how Italy’s bank leaders are anticipating further deal activity after last year’s acquisition of Mediobanca SpA by Banca Monte dei Paschi di Siena SpA , which was backed by the Italian government. Banco BPM purchased asset manager Anima Holding SpA a year ago. Read More: Monte Paschi CEO Sees More Italian Bank Deals After Mediobanca There has been press speculation about interest in Generali , with UniCredit recently increasing its stake to signal that the bank would need to be considered in any potential deal involving Italy’s largest insurer, people familiar with the matter have said . Orcel has ruled out increasing the stake to over 10%. It’s currently at around 9%. Monte Paschi CEO Luigi Lovaglio said in a Bloomberg interview last year that there would likely be more deals in the banking sector. “We are ready to play a central role,” he said. The posturing underscores that a move by one bank would likely trigger counter-actions by others. French lender Credit Agricole SA recently raised its stake in Banco BPM to above 20% to protect its commercial interests. CEO Olivier Gavalda and Banco BPM’s Castagna have signaled in the past few months that they could explore tie-up options between Credit Agricole’s Italian activities and Banco BPM. UniCredit last year abandoned an effort to buy Banco BPM amid government opposition to the deal. A planned tie-up between the asset management ...
(RTTNews) - SK bioscience Co. (302440.KS) reported a first quarter net loss attributable to shareholders of parent company of 33.3 billion korean won compared to a loss of 7.5 billion won, last year. Operating loss widened to 44.5 billion won compared to a loss of 15.1 billion wo
(RTTNews) - SK bioscience Co. (302440.KS) reported a first quarter net loss attributable to shareholders of parent company of 33.3 billion korean won compared to a loss of 7.5 billion won, last year. Operating loss widened to 44.5 billion won compared to a loss of 15.1 billion wo
Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.
Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.